Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Growth Rebounds But Pharma Starts Cutting Prices

Executive Summary

The second quarter has been a period of stabilization for multinational drug makers in China, where the challenges of cost-cutting and a national policy to encourage domestic generics remain. Big pharmas including Novartis and Roche are voluntarily reduce prices for major products, to help them compete, reflecting a new willingness to improve patient access in the world's second-largest pharma market.

Advertisement

Related Content

What’s Separating The Growers And No-Growers In China?
Diabetes Delivers China Strength For Merck
Pfizer Sees Bright Long Term Biosimilar Future In China
Sanofi’s Emerging Markets Steady Despite Venezuela Volatility
AstraZeneca’s Emerging Markets Growth Not All About China
Deep China Price Cuts Reveal Complex Considerations
China Vaccine Scandal: Hundreds Demoted But Root Causes Remain

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097198

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel